ascopubs.org

Comparison of checkpoint inhibitor–based regimens as first-line therapy in advanced hepatocellular carcinoma: A Frequentist Network meta-analysis of randomized clinical trials.

Second-line systematic strategy options for the progression of lenvatinib plus tislelizumab treating unresectable hepatocellular carcinoma: A retrospective study. Transarterial chemoembolization ...
ascopubs.org

Comparison of efficacy between immune checkpoint inhibitors and irinotecan-based chemotherapy as third-line treatment for patients with advanced gastric cancer: A Korean real ...

Genetic alteration and ctDNA mutation profiling of esophageal cancer in Chinese patients. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not include a full ...